|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 17, 2016 ) Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.
Publisher's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Report Highlights
The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Age Related Macular Degeneration.
Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Complete Report at http://www.reportsweb.com/age-related-macular-degeneration-pipeline-review-h2-2016
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Age Related Macular Degeneration Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Age Related Macular Degeneration Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001506614/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001506614/discount
List of Tables
Number of Products under Development for Age Related Macular Degeneration, H2 2016 32
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Development by Companies, H2 2016 (Contd..1) 35
Number of Products under Development by Companies, H2 2016 (Contd..2) 36
Number of Products under Development by Companies, H2 2016 (Contd..3) 37
Number of Products under Development by Companies, H2 2016 (Contd..4) 38
Number of Products under Development by Companies, H2 2016 (Contd..5) 39
Number of Products under Development by Companies, H2 2016 (Contd..6) 40
Number of Products under Development by Companies, H2 2016 (Contd..7) 41
Number of Products under Development by Companies, H2 2016 (Contd..8) 42
List of Figures
Number of Products under Development for Age Related Macular Degeneration, H2 2016 32
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Investigation by Universities/Institutes, H2 2016 44
Comparative Analysis by Late Stage Development, H2 2016 46
Comparative Analysis by Clinical Stage Development, H2 2016 47
Comparative Analysis by Early Stage Products, H2 2016 48
Assessment by Monotherapy Products, H2 2016 183
Number of Products by Top 10 Targets, H2 2016 185
Number of Products by Stage and Top 10 Targets, H2 2016 185
Number of Products by Top 10 Mechanism of Actions, H2 2016 190
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
